AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study of AZD9829 in CD123+ Hematological Malignancies
- First Posted Date
- 2023-12-22
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 104
- Registration Number
- NCT06179511
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs
Recruiting
- Conditions
- Neurofibroma, Plexiform
- First Posted Date
- 2023-12-19
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT06175637
- Locations
- 🇨🇳
Research Site, Nanjing, China
A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 428
- Registration Number
- NCT06173570
- Locations
- 🇪🇸
Research Site, Sevilla, Spain
A Study to Evaluate the Consistency of Oscillometry and Spirometry Test Results in Patients With Confirmed or Suspected Asthma or COPD
Recruiting
- Conditions
- Asthma/ COPD
- Interventions
- Diagnostic Test: suspected asthmaDiagnostic Test: suspected COPDDiagnostic Test: confirmed COPDDiagnostic Test: confirmed asthma
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 800
- Registration Number
- NCT06172777
- Locations
- 🇨🇳
Research Site, Zigong, China
TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause
Completed
- Conditions
- Hypereosinophilic Syndrome (HES)
- Interventions
- Other: no intervention
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2025-02-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT06172751
- Locations
- 🇺🇸
Research Site, Cambridge, Massachusetts, United States
REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in Romania
Active, not recruiting
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Drug: Non interventional study
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT06170671
- Locations
- 🇷🇴
Research Site, Iasi, Romania
A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
Phase 3
Active, not recruiting
- Conditions
- Resistant Hypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 217
- Registration Number
- NCT06168409
- Locations
- 🇻🇳
Research Site, Hochiminh city, Vietnam
An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: AZD4604 Inhalation Powder, 1 mgDrug: [14C]AZD4604 Solution for Infusion 6 μg/mL (NMT 37.0 kBq/5 mL)Drug: [14C]AZD4604 Oral Solution, 4 mg (NMT 37.0 kBq)
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT06157255
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 397
- Registration Number
- NCT06156982
- Locations
- 🇯🇵
Research Site, Osaka, Japan
A Real-world, Multi-center, Prospective, Observational Study for PNH in China
Active, not recruiting
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 724
- Registration Number
- NCT06154512
- Locations
- 🇨🇳
Research Site, Hangzhou, China
© Copyright 2025. All Rights Reserved by MedPath